Literature DB >> 1629967

Envelope glycoprotein and CD4 independence of vpu-facilitated human immunodeficiency virus type 1 capsid export.

X J Yao1, H Göttlinger, W A Haseltine, E A Cohen.   

Abstract

The effect of vpu on the release of human immunodeficiency type 1 capsid proteins was examined in the presence or absence of virus-encoded envelope glycoproteins as well as in cells which constitutively express either the CD4 or CD8 protein. The results show that vpu-mediated facilitated export of capsid proteins from HeLa cells does not require expression of the envelope glycoprotein. The experiments also show that export of virus capsid proteins from HeLa cells facilitated by vpu is not affected by coexpression of either the CD4 or CD8 protein. The vpu protein acts in trans to facilitate export of virus capsid proteins from HeLa cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1629967      PMCID: PMC241384     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

Authors:  P J Maddon; A G Dalgleish; J S McDougal; P R Clapham; R A Weiss; R Axel
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

2.  Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes.

Authors:  R L Willey; F Maldarelli; M A Martin; K Strebel
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  Multiple tandemly repeated binding sites for cellular nuclear factor 1 that surround the major immediate-early promoters of simian and human cytomegalovirus.

Authors:  K T Jeang; D R Rawlins; P J Rosenfeld; J H Shero; T J Kelly; G S Hayward
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

4.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

5.  Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions.

Authors:  J Sodroski; W C Goh; C Rosen; A Tartar; D Portetelle; A Burny; W Haseltine
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

6.  Direct cloning and sequence analysis of enzymatically amplified genomic sequences.

Authors:  S J Scharf; G T Horn; H A Erlich
Journal:  Science       Date:  1986-09-05       Impact factor: 47.728

7.  Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs.

Authors:  S Schwartz; B K Felber; E M Fenyö; G N Pavlakis
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

8.  Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity.

Authors:  B Chesebro; K Wehrly
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 has an additional coding sequence in the central region of the genome.

Authors:  Z Matsuda; M J Chou; M Matsuda; J H Huang; Y M Chen; R Redfield; K Mayer; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

10.  Rev is necessary for translation but not cytoplasmic accumulation of HIV-1 vif, vpr, and env/vpu 2 RNAs.

Authors:  S J Arrigo; I S Chen
Journal:  Genes Dev       Date:  1991-05       Impact factor: 11.361

View more
  41 in total

1.  vpu transmembrane peptide structure obtained by site-specific fourier transform infrared dichroism and global molecular dynamics searching.

Authors:  A Kukol; I T Arkin
Journal:  Biophys J       Date:  1999-09       Impact factor: 4.033

Review 2.  Host restriction factors blocking retroviral replication.

Authors:  Daniel Wolf; Stephen P Goff
Journal:  Annu Rev Genet       Date:  2008       Impact factor: 16.830

3.  The membrane-proximal intracytoplasmic tyrosine residue of HIV-1 envelope glycoprotein is critical for basolateral targeting of viral budding in MDCK cells.

Authors:  R Lodge; J P Lalonde; G Lemay; E A Cohen
Journal:  EMBO J       Date:  1997-02-17       Impact factor: 11.598

4.  The vpu protein of human immunodeficiency virus type 1 plays a protective role against virus-induced apoptosis in primary CD4(+) T lymphocytes.

Authors:  Satoshi Komoto; Shoutaro Tsuji; Madiha S Ibrahim; Yong-Gang Li; Jiranan Warachit; Koki Taniguchi; Kazuyoshi Ikuta
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

5.  The intracytoplasmic domain of gp41 mediates polarized budding of human immunodeficiency virus type 1 in MDCK cells.

Authors:  R Lodge; H Göttlinger; D Gabuzda; E A Cohen; G Lemay
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

Review 6.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

7.  Identification of tRNAs incorporated into wild-type and mutant human immunodeficiency virus type 1.

Authors:  M Jiang; J Mak; A Ladha; E Cohen; M Klein; B Rovinski; L Kleiman
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

8.  Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins.

Authors:  G P Kobinger; A Borsetti; Z Nie; J Mercier; N Daniel; H G Göttlinger; A Cohen
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  T Dorfman; F Mammano; W A Haseltine; H G Göttlinger
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.

Authors:  Yukie Iwabu; Hideaki Fujita; Masanobu Kinomoto; Keiko Kaneko; Yukihito Ishizaka; Yoshitaka Tanaka; Tetsutaro Sata; Kenzo Tokunaga
Journal:  J Biol Chem       Date:  2009-10-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.